Same Indication

Nivolumab vs Ranitidine

Nivolumab vs Ranitidine: Overview

This comparison examines the pharmacological differences between Nivolumab and Ranitidine.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Ranitidine: Competitive H2 receptor antagonist.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Ranitidine — 2-3 hours.

Chemical Properties

Molecular Formula: Ranitidine — C13H22N4O3S.

Molecular Weight: Ranitidine — 314.4050 g/mol.

Type: Nivolumab — Antibody; Ranitidine — Small molecule.